Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Muthu Veeraputhiran

TitleAssociate Professor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentInternal Med, College of Medicine
DivisionInternal Med Hem-Onc
Address4104 Outpatient Circle
Mail Slot # 508
Little Rock AR 72205
Phone501-686-8511
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Muthu Veeraputhiran is a physician in the University of Arkansas for Medical Sciences (UAMS) Department of Internal Medicine. Dr. Veeraputhiran received his medical degree from the Stanley Medical College in his native India. He went on to receive a Masters of Public health from the University of Oklahoma. He then completed residency training in Internal Medicine at Abington Memorial Hospital in Pennsylvania. He has also completed fellowships in Transfusion Medicine at UAMS, Hematology, Oncology, and Bone Marrow Transplantation at Wayne State University, and Bone Marrow Transplantation at Stanford University. Dr. Veeraputhiran is board certified in Clinical Cardiac Electrophysiology from the American Board of Internal Medicine. He is a member of several professional organizations, including the American Society for Blood and Marrow Transplantation, the American Association for Blood Banks, the American Board of Internal Medicine, the American Society of Hematology, and the American Society of Oncology.


    Collapse Research 
    Collapse research activities and funding
    UAMS C25144     (KUMARAN, MUTHU K)Sep 6, 2022 - Sep 5, 2023
    AbbVie Inc
    A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (VIALE-T)
    Role: Principal Investigator

    UAMSC25144     (KUMARAN, MUTHU K)Sep 6, 2022 - Sep 5, 2023
    AbbVie Inc
    A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (VIALE-T)
    Role: Principal Investigator

    UAMS C24929     (KUMARAN, MUTHU K)Aug 17, 2022 - Aug 16, 2023
    Gilead Sciences, Inc.
    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed...
    Role: Principal Investigator

    UAMSC24929     (KUMARAN, MUTHU K)Aug 17, 2022 - Aug 16, 2023
    Gilead Sciences, Inc.
    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed...
    Role: Principal Investigator

    U3UHS45467     (MCELFISH, PEARL A)Feb 1, 2022 - Oct 31, 2023
    Health Resources & Services Administration
    The Vaccine REACH (Reaching Everyone to Achieve Community Health) project
    Role: Principal Investigator

    CPIMP211231     (MCELFISH, PEARL A)Jul 1, 2021 - Jun 30, 2024
    DHHS - Office of Minority Health - Pass Through: Benton County Government
    Benton County REACH Covid Health Literacy
    Role: Principal Investigator

    INCB39110-309     (KUMARAN, MUTHU K)Mar 27, 2020 - Mar 26, 2021
    Incyte Corporation
    GRAVITAS-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (239545)
    Role: Principal Investigator

    INCB39110     (VEERAPUTHIRAN, MUTHU)Mar 27, 2020
    Incyte Corporation
    GRAVITAS-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (239545)
    Role: Principal Investigator

    A041701     (KUMARAN, MUTHU K)Jul 30, 2019
    NIH/Nat. Cancer Institute - Pass Through: Alliance for Clinical Trials in Oncology
    No FP attached
    Role: Principal Investigator

    KD025     (VEERAPUTHIRAN, MUTHU)Jul 26, 2019
    Kadmon Corporation, LLC
    A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study) (IRB# 239363)
    Role: Principal Investigator

    KD025-213     (KUMARAN, MUTHU K)Jul 26, 2019
    Kadmon Corporation, LLC
    No FP attached
    Role: Principal Investigator

    M16     (VEERAPUTHIRAN, MUTHU)Jul 26, 2019
    AbbVie Inc
    Phase 1b Study of Venetoclax and Dinaciclib (MK7965) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (IRB 228481)
    Role: Principal Investigator

    M16-183     (KUMARAN, MUTHU K)Jul 26, 2019
    AbbVie Inc
    No FP attached
    Role: Principal Investigator

    AG-348-C-008     (KUMARAN, MUTHU K)Jul 27, 2018
    Agios Pharmaceuticals, Inc.
    No FP attached
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Zhang A, Miller K, Dykes KC, Ahmed M, Chen EC, Mercadal S, Schwartz M, Tracy SI, Dholaria B, Mukherjee A, Battiwalla M, Logan AC, Ladha A, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor MP, Hill LC, Tsai SB, Sasine JP, Solh MM, Kota VK, Koura D, Veeraputhiran M, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly L. Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. J Clin Oncol. 2024 Oct 17; JCO2400321. PMID: 39418622.
      View in: PubMed
    2. Aldoss I, Roloff GW, Faramand RG, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis YK, Zhang A, Miller K, Sutherland KC, Dykes KC, Ahmed M, Chen EC, Zambrano H, Bradshaw D, Mercadal S, Schwartz MS, Tracy SI, Dholaria B, Kubiak MJ, Mukherjee A, Majhail NS, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy PJ, Logan A, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine JP, Solh MM, Lee CJ, Kota V, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat VA, Shah BD, Muffly L. Impact of Prior Inotuzumab Ozogamicin Treatment on Brexucabtagene Autoleucel outcomes in Adults with B-cell ALL. Blood Adv. 2024 Aug 02. PMID: 39093952.
      View in: PubMed
    3. Pusic I, Lee C, Veeraputhiran M, Minor C, DiPersio JF. Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease. Bone Marrow Transplant. 2024 02; 59(2):282-284. PMID: 38071272.
      View in: PubMed
    4. Fugere T, Baltz A, Mukherjee A, Gaddam M, Varma A, Veeraputhiran M, Gentille Sanchez CG. Immune Effector Cell-Associated HLH-like Syndrome: A Review of the Literature of an Increasingly Recognized Entity. Cancers (Basel). 2023 Oct 26; 15(21). PMID: 37958323.
      View in: PubMed
    5. Lopez-Candales A, Mathur P, Mounsey JP, Veeraputhiran M. Is heart rate in post-hematopoietic stem cell transplant patients clinically relevant? Postgrad Med. 2022 Jan; 134(1):7-10. PMID: 34664532.
      View in: PubMed
    6. Roy AM, Pandey Y, Middleton D, Broadfoot B, Sasapu A, Veeraputhiran M. Intravascular Large B-Cell Lymphoma: A Diagnostic Dilemma. Cureus. 2021 Jul; 13(7):e16459. PMID: 34422488.
      View in: PubMed
    7. Kakadia S, Trotta H, Kurczek L, Burdine L, Veeraputhiran M, Giorgakis E. Early Outcomes of Ruxolitinib in the Treatment of Steroid Refractory Graft-versus-host Disease on Liver Transplant Recipients. Transplantation. 2020 08; 104(8):e247. PMID: 32732859.
      View in: PubMed
    8. Kothari A, Caradine KD, Rico Crescencio JC, Sasapu A, Veeraputhiran MK, Jethava Y, Burgess MJ. Cytomegalovirus appendicitis after hematopoietic stem cell transplantation. Transpl Infect Dis. 2017 Oct; 19(5). PMID: 28708253.
      View in: PubMed
    9. Veeraputhiran M, Yang L, Sundaram V, Arai S, Lowsky R, Miklos D, Meyer E, Muffly L, Negrin R, Rezvani A, Shizuru J, Weng WK, Johnston L. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017 Oct; 23(10):1744-1748. PMID: 28668491.
      View in: PubMed
    10. Kaur V, Swami A, Shebli A, Shalin S, Veeraputhiran M, Emanuel P, Jethava Y. A rare case of blastic plasmacytoid dendritic cell neoplasm with deletion 7q.31, in the setting of heavy pre-treatment with alkylating chemotherapy. J Oncol Pharm Pract. 2017 Oct; 23(7):552-556. PMID: 27559020.
      View in: PubMed
    11. Nandagopal L, Veeraputhiran M, Jain T, Soubani AO, Schiffer CA. Bronchoscopy can be done safely in patients with thrombocytopenia. Transfusion. 2016 Feb; 56(2):344-8. PMID: 26446048.
      View in: PubMed
    12. Veeraputhiran M, Jain T, Deol A, Ayash L, Kim S, Dyson G, Bhutani D, Lum LG, Ratanatharathorn V, Uberti JP, Abidi MH. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2015 Sep; 15(9):531-5. PMID: 26166312.
      View in: PubMed
    13. Veeraputhiran M, Jain T, Cronin S, Al-Kadhimi Z, Abidi MH, Ayash L, Mellert K, Lum LG, Ratanatharathorn V, Uberti JP, Deol A. Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant. J Clin Apher. 2014 Dec; 29(6):293-8. PMID: 24700728.
      View in: PubMed
    14. Veeraputhiran M, Katragadda L, Balamurugan A, Cottler-Fox M. Aldehyde dehydrogenase as an alternative to enumeration of total and viable CD34(+) cells in autologous hematopoietic progenitor cell transplantation. Cytotherapy. 2011 Nov; 13(10):1256-8. PMID: 21905957.
      View in: PubMed
    15. Veeraputhiran MK, Pesek GA, Blackall DP. Strict vs lenient criteria for elution testing: comparison of yields between two tertiary care medical centers. Am J Clin Pathol. 2011 Sep; 136(3):359-63. PMID: 21846910.
      View in: PubMed
    16. Veeraputhiran M, Ware J, Dent J, Bornhorst J, Post G, Cottler-Fox M, Pesek G, Theus J, Nakagawa M. A comparison of washed and volume-reduced platelets with respect to platelet activation, aggregation, and plasma protein removal. Transfusion. 2011 May; 51(5):1030-6. PMID: 20946201.
      View in: PubMed
    17. Veeraputhiran M, Theus JW, Pesek G, Barlogie B, Cottler-Fox M. Viability and engraftment of hematopoietic progenitor cells after long-term cryopreservation: effect of diagnosis and percentage dimethyl sulfoxide concentration. Cytotherapy. 2010 Oct; 12(6):764-6. PMID: 20353307.
      View in: PubMed
    18. Veeraputhiran M, Sundermeyer M. Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin. Clin Lung Cancer. 2008 Jul; 9(4):232-4. PMID: 18650173.
      View in: PubMed
    Veeraputhiran's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description